User friendly reference guide to some key facts on malaria chemoprophylaxis

Very Important: refer to UK Malaria Guidelines- see below for details, BNF & Summary of Product Characteristics (SmPCs on the emc) for further details, especially on contra-indications, caution in use, special notes, precautions and less common side effects for all drugs. Links to individual drugs found below. © Jane Chiodini. Updated November 2023

Generic Name	Chloroquine	Mefloquine	Doxycycline	Atovaquone / Proguanil
Trade Name	<u>Avloclor</u> ®	Lariam [®]	Doxycycline (non-proprietary)	Malarone
Click on drug	<u>Malarivon</u>		<u>Vibramycin</u> ®	Malarone Paediatric
names for SmPC				Atovaquone/Proguanil (Non- proprietary)
Available forms	Tablet (Avloclor)	Tablet only.	Capsules, generic doxycycline	Tablet only
	Malarivon Syrup for		Dispersible tablet form, Vibramycin only.	(Paediatric dose tablets available for those 40 kgs in
	children			weight and lower).
Most common	GI disturbances and	Gastrointestinal disturbances	Oesophagitis (unless taken correctly)	Headache
side effects	headache	Headache	Vaginal candidiasis	Abdominal pain
(but see SmPC –	Itching especially in	Loss of balance, dizziness	Photosensitivity may occur which is mostly mild	Diarrhoea
section 4.8 for	those of African	N.B. See <u>Risk Management</u>	& transient	
more detail)	descent	Materials on the emc		
More serious side	Important to refer to section 4.8 of the SmPC for each individual drug.			
effects	Note: CHLOROQUINE and MEFLOQUINE are CONTRAINDICATED in those with EPILEPSY. Also see the Chemoprophylaxis section in the Malaria Guidelines page 27			
Dosage and	310 mgs base	250mg (1 tablet) weekly	100mg (1 capsule) daily	Combined tablet of atovoquone / proguanil (1 tablet)
administration	(2 tablets) weekly		Take capsules after food in an upright position,	taken daily with food or milky drink at the same time
dummistration	(2 tublets) weekly		do not lie down afterwards for at least 1 hour	each day.
	Refer to LIK Malaria	Guidelines or current BNF for child	after ingestion to reduce likelihood of	
		hylactic antimalarials – useful charts	oesophageal irritation and ulceration.	Paediatric tablets given for persons 11 - 40 kgs in weight
	are in the <u>UK Malaria Guidelines</u> – pages 38-39.			however UK malaria guidelines discuss use from 5kgs
		de in decision of doses than age in		[off license] in special circumstances.
	children over six months of age. NaTHNaC chart here.			
Commencement	1 week before	2-3 weeks before entering	1 or 2 days before entering malarious area.	1 or 2 days before entering the malarious area.
of medication	entering malarious	malarious area.	, , ,	
	area			
Duration of	All time in	All time in malarious area and for 4	All time in malarious area and for 4 weeks after	Take daily taking during period of stay in malarious area
course	malarious area and	weeks after leaving. Take on the	leaving.	and for 7 days after leaving malarious area.
	for 4 weeks after	same day of the week each time.		
	leaving on same			
	day each week.			
Duration of long	Several years	UK Malaria Guidelines suggest up	UK Malaria Guidelines suggest at least up to 2	UK Malaria Guidelines state 'can be used confidently for
term use – see	Consider	to three years in the absence of	years and longer use possible if justified by risk	travel up to one year. Longer term use possible if
table 10 (p76) in	ophthalmic exam at	side effects.	of exposure.	justified by the risk of exposure to malaria'.
malaria guidelines	6 yrs use onwards.			
Prescribing	Available OTC for	Available only on private	Available only on private prescription.	Available only on private prescription.
information	malaria	prescription.	Local policy may vary.	However, one brand <u>Maloff Protect</u> can be supplied in a
	chemoprophylaxis.	Local policy may vary.		pharmacy as a <u>P medicine</u> (needing no prescription).

PLEASE NOTE: not covered on this chart but for PREGNANCY, BREAST FEEDING and PLANNED PREGNANCY whilst travelling to a malarious area – the UK Malaria Guidelines should ALWAYS be referred to – please see especially pages 55-57.

AND for help with any complex queries contact the UKHSA Malaria Reference Laboratory (see further details this e mail service - click HERE) or ring the NaTHNaC helpline.